U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07045558) titled 'HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC' on June 10.
Brief Summary: Patients with unresectable HCC will be enrolled in the cohort and will receive the combination therapy of HAIC and atezolizumab plus bevacizumab. The objective response rate is the primary endpoint, and the secondary endpoint includes disease control rate, conversion rate, pathologic complete response, major pathologic response, progression-free survival, recurrence-free survival, overall survival, quality of life, and safety.
Study Start Date: Aug. 01
Study Type: OBSERVATIONAL
Condition:
Unresectable Hepatocellular Carcinoma
Recruitment Status:...